-
Media ReleaseFDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
-
Media ReleaseNovartis announces FDA filing acceptance of Xolair® (omalizumab) prefilled syringe for self-administration across all indications
-
Media ReleaseNovartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
-
Media ReleaseNovartis Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
-
Media ReleaseNovartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery
-
Media ReleaseNovartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)
-
Media ReleaseNovartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease
-
Media ReleaseNovartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14
-
Media ReleaseNovartis US Foundation supports telehealth programs to provide access to care for New Jersey's most vulnerable communities
-
Media ReleaseNovartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
-
Media ReleaseNovartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
-
Media ReleasePublic-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People